Tag: GSK

LITIGATION ROUND-UP

Settlements & Resolutions GlaxoSmithKline (GSK) agreed to pay $105 million to resolve allegations that it illegally marketed its asthma drug Advair and its antidepressants Paxil and Wellbutrin for uses not approved by the US Food and Drug Administration (FDA) in violation of state consumer protection laws.  The multi-state settlement included 44 states […]

Law360 Article: “GSK Announcement May Change Industry Speaker Programs”

As we previously posted, GlaxoSmithKline (GSK) recently announced that it intends to end the practice of paying health care professionals to speak on the company’s behalf in a promotional manner.  While GSK was the first pharmaceutical company to announce this change, other pharmaceutical and medical device manufacturers may be considering similar changes.  […]

GSK Will Stop Paying HCP Speakers, Expanding Sales Rep Compensation Structure Globally

GlaxoSmithKline (GSK) announced this week that it will stop compensating health care professionals (HCPs) for speaking on the company’s behalf regarding its products and related disease areas to other HCPs and attendees who potentially could prescribe or influence the prescribing of the company’s products.  GSK also announcenced its intent to educate HCPs by strengthening its own medical and scientific capabilities, improving the company’s multi-channel capability to provide appropriate and convenient […]

LITIGATION ROUND-UP

Settlements On July 24, 2013, GlaxoSmithKline (GSK) announced a settlement in principle with the Attorneys General of eight states related to the development and marketing of Avandia and a separate settlement with the Attorney General of Louisiana totaling $229 million.  GSK previously paid $3 billion to settle civil and criminal allegations related to the marketing of Avandia and […]

LITIGATION ROUND-UP

Settlements The U.S. Department of Justice (DOJ) announced on July 18, 2013 that pharmaceutical manufacturer Mallinckrodt LLC agreed to pay $3.5 million to settle a civil False Claims Act suit. The complaint alleged that Mallinckrodt paid illegal kickbacks to health care professionals in the form of speaker honoraria, clinical trials funding, and honoraria […]